ESMO21: KEYNOTE-826 trial demonstrates survival benefit of pembrolizumab for cervical cancer

Data presented from the KEYNOTE-826 clinical trial at the ESMO Congress 2021 (16−21 September 2021; Virtual) has highlighted that adding pembrolizumab to standard first-line treatment extends survival by 8 months for patients with recurrent, persistent or metastatic cervical cancer. “The KEYNOTE-826 study is a new milestone, demonstrating a very relevant increment in the overall survival of patients with this condition and, for the first time, showing that incorporating immunotherapy into front line treatment can change the natural history of the disease,” commented Antonio González-Martín from Clínica Universidad de Navarra (Madrid, Spain). You may also like: ASCO21: Stick with standard of...